OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Neurology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Facial Numbness, Dysarthria, Muscle Atrophy, and Weakness in a Young Patient	451
Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis	408
Diplopia and Ptosis in an Older Woman	363
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	345
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	316
Early Posttraumatic Seizures—Putting Things in Perspective	306
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	258
Error in Author Name	238
Rizatriptan vs Placebo for Attacks of Vestibular Migraine	231
Origin of Transthyretin in Cerebral Amyloid Angiopathy	212
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	198
Association Between Increased Seizures During Rewarming After Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy and Abnormal Neurodevelopmental Outcomes at 2-Year Follow-up	196
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	189
Somebody to Love	187
Equipping AI for Unbiased and Inclusive Neurology	185
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	182
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	182
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	182
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study	181
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	177
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis	175
Automated Imaging Differentiation for Parkinsonism	173
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	167
JAMA Neurology	164
The Neurologist’s Imperative in Brain Death	158

Magnetic Resonance Imaging Features of Tropical Candidal Meningoencephalitis	155
Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach	149
Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke	146
Is It Really Itching?	145
JAMA Neurology	145
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts	138
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	137
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers	133
Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome	129
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	127
Time to Change the Current Clinical Classification of Multiple Sclerosis?	124
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation	123
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis	121
Advanced Practice Clinicians—Neurology’s Underused Resource	120
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis	116
Error in Abstract	112
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke	110
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy	108
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy	108
Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care?	108
Do Neurologists Need a Goldwater Rule?	108
Disentangling Workflow Paradigms and Treatment Decision-making in Acute Ischemic Stroke	107
Error in Figure	106
Histologic Anatomy of Neurocysticercosis	103
Error in Additional Contributions	97
Association of Cardiovascular Events With Spouse’s Subsequent Dementia	96
Sleep Recording for the Diagnosis and Treatment of Paraplegia	93
Is It Really Itching?—Reply	93
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor	91
JAMA Neurology	89
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions	88
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment	87
Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply	87
Intra-Arterial Tenecteplase After Successful Reperfusion in Large Vessel Occlusion Stroke	87
Error in Figure	85
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core	85
Visual Neglect After an Isolated Lesion of the Superior Colliculus	85
Role of the X Chromosome in Alzheimer Disease Genetics	84
Spontaneous AICA Dissection Presenting With Isolated Audiovestibular Loss	83
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	82
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	81
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology	81
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	77
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias	76
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	76
JAMA Neurology	75
Acute Myelopathy in a Man With Cutaneous Papules	75
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis	74
JAMA Neurology	74
Error in Text	73

Perceived CTE and Suicidality—Is Perception Reality?	73
Error in Figures	72
Error in Key for Figure 3	72
AI Devices in Neurology—Moving From Diagnosis to Prognosis	71
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage	71
Functional Impairment in Individuals With Prodromal or Unrecognized Parkinson Disease	70
Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease	70
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome	68
A Rare Neurological Presentation of Kikuchi-Fujimoto Disease	67
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak	67
Visualization of Parkinsonian Tongue Tremor on Ultrasonography	67
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura	67
Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome	67
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	67
The New Era of Automated Electroencephalogram Interpretation	67
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease	66
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis	66
The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo	66
Comparison of Perinatal Outcomes for Women With and Without Epilepsy	66
Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	66
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients	65
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	65
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	64
Repairing Our View of Dementia	63
The Choreoathetotic Movement of Paroxysmal Nonkinesigenic Dyskinesia	62
Error in Text	61
Concerns Remain Regarding Ambient NO₂ Exposure and the Risk of Parkinson Disease—Reply	61
Choosing the Best Antiseizure Medication—Can Artificial Intelligence Help?	61
Livedo Reticularis—A Presenting Sign of Neuromyelitis Optica Spectrum Disorder	59
JAMA Neurology Peer Reviewers in 2021	59
Error in Title	59
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply	58
Addition of Video Titles	58
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?	57
Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases	57
Life Expectancy for Patients With Sporadic Creutzfeldt-Jakob Disease	57
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies	56
SARS-CoV-2 Vaccination and Neuroimmunological Disease	56
Adverse Childhood Experiences, Toxic Stress, and Trauma-Informed Neurology	55
Possible Explanations for Hearing Loss in Parkinson Disease	55
IWG and AA Criteria—Where the Differences Matter—Reply	54
Benefits and Risks of Periconceptional Folic Acid Supplementation	53
Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow	53
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	53
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	53
Coma Prognostication After Acute Brain Injury	53
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	52
Monogenic Stroke—Can We Overcome Nature With Nurture?	52
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest	52
Association Between Acute Myocardial Infarction and Cognition	52
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience—Reply	51
A Woman With Eosinophilic Brainstem Meningoencephalitis	50
The Perils and Pitfalls of Global Engagement	50
JAMA Neurology	50
Addition of Nonauthor Collaborators and a Supplement	49
How Is the X Chromosome Involved in Alzheimer Disease?	49
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness	48
Views From Both Sides of the White Coat	47
Transcarotid Artery Revascularization for Stroke Prevention—Multiple Elephants in the Room	47
Errors in Figure 2 and the Short Title	45
Citius, Fortius, Altius—Understanding Which Components Drive Exercise Benefits in Parkinson Disease	45
Gantenerumab in Dominantly Inherited Alzheimer Disease—Reply	45
TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis	44
Discerning the Role of Autoimmunity and Autoantibodies in Epilepsy	44
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage	44
Error in Author Affiliation	44
Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management	44
Medical Forecasting—A Skill Set Worthy of Attention	44
Structural Inequities for Historically Underserved Communities in the Adoption of Stroke Certification in the United States	43
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis	43
The End Justifies the Means—A Call for Nuance in the Increasing Nationwide Adoption of Stereoelectroencephalography Over Subdural Electrode Monitoring in the Surgical Evaluation of Intractable Epileps	43
Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria	43
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors	43
GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial	43
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	42
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	42
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died	41
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	41
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis	41
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy	40

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	40
Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia	40
Modern Neurology Training Is Failing Outpatients	39
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man	39
Statewide Emergency Medical Services Protocols for Suspected Stroke and Large Vessel Occlusion	39
Error in Title	38
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	38
Acute Ischemic Stroke Care Quality Improvement	38
JAMA Neurology	38
Error in Figures 2 and 3	38
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	37
JAMA Neurology	37
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	37
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	37
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia	36
Venture Capital Investment in Neurology Companies	36
Error in Open Access Status	36
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	35
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	35
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	35
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	35
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	34
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	34
Neurologic Complications of Smallpox and Monkeypox	34
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	34
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	33
CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment	33
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	33
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	33
Batoclimab vs Placebo for Generalized Myasthenia Gravis	33
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	32
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	32
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	32
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	32
Risk Factors for Young-Onset Dementia in the UK Biobank	32
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	31
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	31
Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death	31
Error in Methods	30
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke	30
Error in Figure 2	30
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	30
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	30
A Funeral for a Neurologist	29
Entering Medicine as a Physician and a Patient	29
Remembering the Physician’s Humanity—Physicians Are Humans Too	29
Light Reading—The Gravity of Postoperative Care	29
Association Between Use of Angiotensin Receptor Blockers and Incidence of Epilepsy in Patients With Hypertension—Reply	29
Neuro-Advocacy—Professionalism in Action	29
Inducers and Cardiovascular Risk—Potential Role for Lowered Drug Exposure	29
Paused—A Residency Interrupted	29
Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma	29
A New Dystonia Phenotype in Wilson Disease	28
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms	28
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	28
Association of Tourette Syndrome and Chronic Tic Disorder With Violent Assault and Criminal Convictions	28
Gene Therapy vs Cochlear Implantation in Restoring Hearing Function and Speech Perception for Individuals With Congenital Deafness	27
Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome	27
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	27
APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome—Implications for Clinical Trials and Treatments for All	27
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers	27
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?	27
Lecanemab Treatment in a Specialty Memory Clinic	27
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor	27
Multiple Facial Ulcers Following a Stroke	26
Error in Title	26
JAMA Neurology	26
Error in Figure 1	26
Error in Figure 2B	26
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019	26
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection	25
How SAFE Is Real-world Use of Spinal Cord Stimulation Therapy for Chronic Pain?	25
Bilateral Calcification of the Meckel Cave Causing Hemicrania Continua	25
A Decision With Love	25
Abnormal Movements in Bickerstaff Brainstem Encephalitis Mimicking Anti–N-Methyl-d-Aspartate Receptor Encephalitis	25
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply	25
Anticoagulation in ESUS—Back From the Dead?	24
Risk Factors and Prognosis of Early Posttraumatic Seizures in Moderate to Severe Traumatic Brain Injury	24
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database	24
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease	24
Research Criteria for the Behavioral Variant of Alzheimer Disease	24
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events	24
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases	24
Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage	24
Error in Title	23
JAMA Neurology	23
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease	23
JAMA Neurology—The Year in Review, 2023	23
Combined Physiotherapy and Cognitive Behavioral Therapy for Functional Movement Disorders	23
Errors in Results in Abstract and Text and in Table 1	23
The Cynicism of the Seronegative	22
Functional Impairment Preceding Parkinson Disease Diagnosis—What’s in a Prodrome?	22
Sex Differences in Case-Fatality Rates of Stroke—Reply	22
Error in the Author Affiliations	22
Oncogenic Pathways Provide Clue to the Etiology of Human Mesial Temporal Lobe Epilepsy	22